Ajanta Pharmaceuticals Ltd.
AJANTPHARM · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹1,358.64.
Piotroski F-score 4/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%25.4%
- ✓Low debt (D/E < 0.5)0.06x
- ✓Positive free cash flow
- ✓Revenue growth > 10%22%
- ✓Earnings growing19%
- ✓Net margin ≥ 10%19.4%
- ✓Current ratio > 1.52.64
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 16.24
- ✕Piotroski ≥ 74/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Strong return on equity (25.4%).
- •Lightly leveraged balance sheet.
- •Healthy profit margin (19.4%).
- •Financially solid — Altman Z 16.24.
Opportunities
- •Earnings growing (19% YoY).
- •Revenue growing (22% YoY).
- •Trading in our value buy zone versus sector peers.
Threats
- •Trades ~44% above our estimated fair value.
About Ajanta Pharmaceuticals Ltd.
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, and pain management
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.